CHOLEBRINE
LOE Approachingiocetamic acid
NDAORALTABLET
Approved
May 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 10h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLEBRINE (iocetamic acid) is an oral tablet small molecule approved in 1973 as a cholagogue and diagnostic agent for hepatobiliary imaging. It stimulates bile secretion and is used to visualize the gallbladder and biliary tract function. The drug works by promoting choleresis, aiding in both therapeutic and diagnostic applications in gastroenterology.
LOE Approaching
With LOE approaching, this mature product faces declining revenue and shrinking commercial team opportunities; remaining roles focus on legacy brand maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLEBRINE offers minimal career advancement opportunity as a legacy product in LOE phase with zero linked jobs and no active development pipeline. Roles available are primarily defensive, focused on managing decline rather than building brand equity or innovation.
Brand Manager (legacy products)Field Sales (niche distribution)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.